1. Home
  2. CRSP vs SKYW Comparison

CRSP vs SKYW Comparison

Compare CRSP & SKYW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • SKYW
  • Stock Information
  • Founded
  • CRSP 2013
  • SKYW 1972
  • Country
  • CRSP Switzerland
  • SKYW United States
  • Employees
  • CRSP N/A
  • SKYW N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • SKYW Air Freight/Delivery Services
  • Sector
  • CRSP Health Care
  • SKYW Consumer Discretionary
  • Exchange
  • CRSP Nasdaq
  • SKYW Nasdaq
  • Market Cap
  • CRSP 4.9B
  • SKYW 4.1B
  • IPO Year
  • CRSP 2016
  • SKYW N/A
  • Fundamental
  • Price
  • CRSP $57.68
  • SKYW $116.66
  • Analyst Decision
  • CRSP Buy
  • SKYW Strong Buy
  • Analyst Count
  • CRSP 16
  • SKYW 4
  • Target Price
  • CRSP $70.73
  • SKYW $126.75
  • AVG Volume (30 Days)
  • CRSP 3.7M
  • SKYW 414.4K
  • Earning Date
  • CRSP 08-04-2025
  • SKYW 07-24-2025
  • Dividend Yield
  • CRSP N/A
  • SKYW N/A
  • EPS Growth
  • CRSP N/A
  • SKYW 132.99
  • EPS
  • CRSP N/A
  • SKYW 9.81
  • Revenue
  • CRSP $37,675,000.00
  • SKYW $3,840,870,000.00
  • Revenue This Year
  • CRSP $28.31
  • SKYW $12.73
  • Revenue Next Year
  • CRSP $268.05
  • SKYW $4.70
  • P/E Ratio
  • CRSP N/A
  • SKYW $11.91
  • Revenue Growth
  • CRSP N/A
  • SKYW 20.45
  • 52 Week Low
  • CRSP $30.04
  • SKYW $64.61
  • 52 Week High
  • CRSP $71.13
  • SKYW $135.57
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 52.32
  • SKYW 66.41
  • Support Level
  • CRSP $61.13
  • SKYW $108.23
  • Resistance Level
  • CRSP $69.58
  • SKYW $119.44
  • Average True Range (ATR)
  • CRSP 3.89
  • SKYW 3.17
  • MACD
  • CRSP -0.71
  • SKYW 0.16
  • Stochastic Oscillator
  • CRSP 28.46
  • SKYW 75.20

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About SKYW SkyWest Inc.

SkyWest Inc offers commercial air services in the United States, Canada, Mexico, and the Caribbean. Additionally, it leases aircraft to capable users to help generate revenue. Generally, SkyWest provides regional flights, and utilizes its smaller, lower-cost aircraft to carry passengers that booked tickets through airlines. It partners with carriers across the world to fly and operate aircraft for a fee. SkyWest may use the carriers's brand and ground support to coordinate marketing and easily transport passengers. The company has two reportable segments: SkyWest Airlines, which generates maximum revenue, and SkyWest Leasing.

Share on Social Networks: